pva will be a billion-dollar company soon !!!

I'm Holding my shares, this stock is about to go thru the Roof.Psivida has Tremendous Upside Potential !!

BrachySil ,another Psivida Blockbuster !!

http://www.reuters.com/article/pressRelease/idUS127148+02-Dec-2008+BW20081202

pSivida’s BrachySil Pancreatic Cancer Treatment Featured on the BBC

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a drug delivery company, today
announced that its lead oncology product, BrachySilTM for the treatment of
pancreatic cancer, has been featured in a BBC1 primetime investigative news
report, ‘The One Show’ aired at 7pm GMT on November 18, 2008.

The news report followed two patients undergoing treatment for different cancers
at the Experimental Cancer Medicine Centre (ECMC) in Birmingham, United Kingdom.
Patient two, aged 60 years was diagnosed with pancreatic cancer in July of 2008.
The patient is being treated with BrachySil in combination with Gemcitabine
(standard chemotherapy). In the report, the patient expressed that his quality
of life had been positively transformed by the treatment.

“Around about June I was very ill, I couldn’t get comfortable, I couldn’t sleep,
I wasn’t eating and was basically wasting away,” said the patient. Following a
course of BrachySil treatment the patient said, “The course of my life has
improved 100%. I’ve come from lying down and not thinking that I would last much
longer, to looking forward to Christmas, and now what lies beyond Christmas.”

Pancreatic cancer is the fourth most frequent cause of cancer death, and at
least 80% of patients present with inoperable locally advanced or metastatic
disease. The median survival for these patients following diagnosis is typically
less than six months with standard chemotherapy. Accordingly, there is
significant clinical and market demand for more effective therapies.

BrachySil entered a dose ranging study earlier this year with a total of six
patients to be enrolled at two centers in the UK (Guy’s and St Thomas’ NHS
Foundation Trust, and University Hospital, Birmingham). The study will determine
the safety of escalating radiation doses of the BrachySil™ device, with tumor
response as a secondary end point.

The results of a safety study presented in January at the American Society of
Clinical Oncology-GI showed that BrachySil, in combination with standard
chemotherapy, was well tolerated with no clinically significant adverse events
related to the device. Data showed disease control in 82% of patients and an
overall median survival of 309 days. BrachySil was found to be easily
deliverable by endoscopic ultrasound.

Managing Director of pSivida Corp., Dr Paul Ashton said, “We are very pleased to
be developing BrachySil as a potentially effective treatment for pancreatic
cancer, a devastating disease for patients and their families”.